With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T cell therapy—potentially helping to offset loss-of-exclusivity headwinds. Bristol Myers Squibb could soon be adding another indication to Breyanzi’s label, with a topline readout from a mid-stage study on Monday pointing to the CAR T cell therapy’s potential in marginal zone lymphoma.
The pharma did not provide specific data from the Phase II TRANSCEND FL trial in its press announcement, revealing only that Breyanzi met its primary efficacy endpoint, eliciting a “statistically significant and clinically meaningful” overall response rate. Breyanzi also met the trial’s key secondary endpoint of complete response rate, while also demonstrating a durable response profile.